Infection Control Market Overview: Key Drivers, Segments, and Future Outlook (2024-2030)

Browse 635 market data Tables and 59 Figures spread through 616 Pages and in-depth TOC on "Infection Control Market by Product (Sterilization Equipment: Hydrogen Peroxide, Ethylene, Radiation), Service (ETO, Gamma, E-Beam), Disinfection (Wipes, Disinfector), Gown, Mask, Endoscope Reprocessing, End User (Hospital, Pharma) - Global Forecast to 2030
The global Infection Control Market [https://www.marketsandmarkets.com/Market-Reports/infection-control-market-1084.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=infectioncontrolmarket], valued at US$54.32 billion in 2024, stood at US$57.31 billion in 2025 and is projected to advance at a resilient CAGR of 6.3% from 2025 to 2030, culminating in a forecasted valuation of US$77.67 billion by the end of the period. The infection control market is experiencing significant growth driven by several key factors. The rising prevalence of healthcare-associated infections (HAIs) and the increasing number of surgical procedures underscore the critical need for effective infection prevention strategies. Advancements in reprocessing technologies enhance the efficiency and safety of sterilization processes, while the growing emphasis on sterilizing and disinfecting food products addresses public health concerns. Innovations in sterilization equipment technology further improve outcomes by offering more reliable and advanced solutions. Additionally, the growing trend of outsourcing services among pharmaceutical companies, medical device manufacturers, and hospitals reflects a strategic shift towards specialized infection control expertise, collectively fueling market expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1084 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1084&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=infectioncontrolmarket]

By treatment, the infection control market is divided into five main segments based on treatment: sterilization products & services, cleaning & disinfection products, protective barriers, endoscope reprocessing products, and other infection control products. Cleaning and disinfection products are crucial in infection control as they eliminate harmful pathogens from surfaces, equipment, and environments, thereby breaking the chain of infection. These products are widely used across hospitals, laboratories, pharmaceutical facilities, and public spaces to maintain hygiene and prevent cross-contamination. Their frequent and routine application makes them a first line of defense against healthcare-associated infections, supporting regulatory compliance and patient safety. Additionally, their broad applicability, ease of use, and critical role in preventive and corrective infection control measures make them the most widely adopted product category in the market.

By end user, the global active pharmaceutical ingredients (API) market has been segmented into synthetic APIs and biotech APIs. In 2024, the synthetic APIs segment held the largest share of the market. This dominance is mainly due to the increasing regulatory approvals for new drugs and advancements in chemical synthesis techniques. Synthetic APIs offer several advantages over large-molecule or biologic drugs. They can be designed to provide strong therapeutic effects at very small doses, often below 10 mg or even at microgram levels. The reduced quantity requirements, coupled with improvements in chemical manufacturing technologies, make synthetic APIs cost-effective while maintaining high efficacy. The analytical methods for developing synthetic APIs are highly refined, ensuring consistent quality and therapeutic performance. In contrast, innovative APIs, which include large molecules such as proteins and monoclonal antibodies, require more complex manufacturing processes and larger quantities for effective dosing, making them relatively expensive. Despite this, biotech APIs are increasingly adopted for specialized therapies targeting complex diseases. Overall, the combination of efficiency, scalability, and technological maturity keeps synthetic APIs as the dominant segment. Biotech APIs continue to grow in niche and high-value therapeutic areas, reflecting a balanced but evolving market landscape.

By geography, the infection control market is segmented into six major segments, namely, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC Countries. North America held the largest market share in the infection control market in 2024, primarily due to its advanced healthcare infrastructure, stringent regulatory standards, and strong emphasis on patient safety. This dominance is expected to continue during the forecast period. High adoption of sterilization and disinfection technologies, rising surgical volumes, and the prevalence of healthcare-associated infections drive consistent demand. Additionally, the presence of leading industry players and substantial healthcare spending further strengthens the region's market dominance.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=1084 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=1084&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=infectioncontrolmarket]

Prominent players in the infection control market include STERIS (US), Reckitt Benckiser Group plc. (UK), Fortive (US), Sotera Health (US), Solventum (US), Getinge AB (Sweden), Ecolab, Inc. (US), Olympus Corporation (Japan), Envista (US), and PAUL HARTMANN AG (Germany).

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=infection-control-market-overview-key-drivers-segments-and-future-outlook-20242030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/infection-control-market-1084.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.